1. Lott D, Krause A, Seemayer CA, et al. Modeling the effect of the selective S1P(1) receptor modulator ponesimod on subsets of blood lymphocytes. Pharm Res. 2017;34(3):599–609.
2. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011;337(2):547–56.
3. Janssen Pharmaceuticals. PONVORYTM (ponesimod) tablets: US Prescribing information 2021. https://www.janssen.com/. Accessed 22 Mar 2021.
4. Janssen Pharmaceuticals. Janssen announces U.S. FDA approval of PONVORY™ (ponesimod), an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio® (teriflunomide) in reducing annual relapses and brain lesions [media release]. 25 Mar 2021. https://www.janssen.com/.
5. European Medicines Agency. Ponvory (ponesimod). 2021. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ponvory. Accessed 25 Mar 2021.